NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 02 04:00PM ET
1.82
Dollar change
-0.02
Percentage change
-1.36
%
Index- P/E- EPS (ttm)-0.66 Insider Own- Shs Outstand83.81M Perf Week2.53%
Market Cap167.73M Forward P/E6.90 EPS next Y0.26 Insider Trans- Shs Float- Perf Month-15.65%
Enterprise Value116.19M PEG- EPS next Q-0.37 Inst Own0.17% Short Float- Perf Quarter-4.71%
Income-53.51M P/S12.29 EPS this Y121.66% Inst Trans1.72% Short Ratio2.17 Perf Half Y-13.78%
Sales13.65M P/B16.68 EPS next Y84.87% ROA-33.61% Short Interest0.05M Perf YTD-1.09%
Book/sh0.11 P/C2.01 EPS next 5Y21.54% ROE-160.99% 52W High3.51 -48.16% Perf Year-6.19%
Cash/sh0.91 P/FCF- EPS past 3/5Y5.60% -13.71% ROIC-166.06% 52W Low1.29 41.09% Perf 3Y-30.53%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-1.57% -29.28% Gross Margin- Volatility6.27% 4.80% Perf 5Y-71.84%
Dividend TTM- EV/Sales8.51 EPS Y/Y TTM-552.37% Oper. Margin-468.14% ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.60 Sales Y/Y TTM-75.67% Profit Margin-392.04% RSI (14)39.24 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio2.60 EPS Q/Q-164.84% SMA20-5.45% Beta0.21 Target Price6.82
Payout- Debt/Eq3.51 Sales Q/Q-73.83% SMA50-12.02% Rel Volume0.23 Prev Close1.85
Employees181 LT Debt/Eq2.52 EarningsMay 13 BMO SMA200-7.46% Avg Volume23.67K Price1.82
IPOOct 17, 2019 Option/ShortNo / Yes EPS/Sales Surpr.-29.54% -52.48% Trades Volume5,448 Change-1.36%
Date Action Analyst Rating Change Price Target Change
Sep-03-21Upgrade SVB Leerink Mkt Perform → Outperform $7
Dec-15-20Downgrade SVB Leerink Outperform → Mkt Perform $7 → $5
Nov-24-20Initiated Goldman Neutral $4.75
Jun-17-25 01:00AM
Jun-13-25 01:00AM
May-27-25 01:00AM
May-23-25 01:00AM
01:00AM
01:00AM Loading…
May-19-25 01:00AM
May-15-25 01:00AM
May-13-25 01:00AM
May-12-25 01:00AM
May-06-25 01:00AM
Apr-30-25 11:30AM
Apr-29-25 03:00PM
Apr-28-25 01:00AM
Apr-24-25 01:35AM
Apr-23-25 01:00AM
01:00AM Loading…
Apr-16-25 01:00AM
01:00AM
Apr-05-25 11:00AM
Apr-03-25 01:00AM
Mar-27-25 04:49PM
02:00AM
Mar-26-25 02:00AM
Mar-25-25 02:00AM
Mar-21-25 09:10AM
Mar-20-25 02:00AM
Feb-27-25 01:00AM
Feb-17-25 01:02AM
Jan-27-25 01:00AM
Jan-21-25 01:00AM
Jan-16-25 01:00AM
01:00AM Loading…
Jan-10-25 01:00AM
Dec-20-24 01:00AM
Dec-10-24 06:30AM
Dec-09-24 01:00AM
Dec-06-24 01:00AM
Dec-03-24 01:00AM
Nov-20-24 01:00AM
Nov-19-24 01:00AM
Nov-13-24 01:00AM
Nov-08-24 01:00AM
Nov-07-24 01:00AM
Oct-29-24 02:00AM
Oct-14-24 01:00AM
Sep-30-24 01:00AM
Sep-23-24 01:00AM
Sep-12-24 01:00AM
Sep-09-24 01:00AM
Sep-05-24 01:00AM
Sep-04-24 01:00AM
Aug-01-24 01:00AM
Jul-25-24 01:00AM
Jun-18-24 01:00AM
Jun-17-24 01:00AM
Jun-10-24 07:32AM
Jun-04-24 01:00AM
May-28-24 01:00AM
May-24-24 01:00AM
May-23-24 04:00PM
May-21-24 01:00AM
May-15-24 01:00AM
May-14-24 01:00AM
May-07-24 01:00AM
Apr-15-24 01:00AM
01:00AM
Apr-10-24 12:00PM
01:00AM
Apr-09-24 01:00AM
Apr-05-24 03:34AM
Mar-22-24 11:33AM
Mar-21-24 02:00AM
Mar-19-24 02:00AM
Mar-14-24 02:00AM
Mar-06-24 01:00AM
01:00AM
Feb-21-24 01:00AM
Jan-12-24 01:00AM
Jan-04-24 01:00AM
12:59AM
Dec-19-23 01:00AM
Dec-18-23 01:00AM
Dec-11-23 01:00AM
Dec-10-23 01:00AM
Nov-27-23 01:00AM
Nov-15-23 10:36AM
Nov-14-23 01:00AM
Nov-07-23 01:00AM
Nov-03-23 02:00AM
Oct-27-23 01:00AM
Oct-19-23 01:00AM
Oct-16-23 01:00AM
Oct-09-23 01:00AM
Oct-05-23 01:00AM
Sep-22-23 01:00AM
Sep-14-23 01:00AM
Aug-29-23 01:00AM
Aug-10-23 01:00AM
Jul-11-23 01:00AM
Jul-07-23 01:00AM
Jun-26-23 01:00AM
01:00AM
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Nordisk A/S10% OwnerMay 30 '25Proposed Sale2.14921,8971,972,859May 30 08:31 AM